Kanna vs CBD: What's the Difference?
Share
Over the past few years, CBD has become one of the most widely recognised natural botanicals in Spain and across Europe. Walk into any health shop in Barcelona and you'll find shelves lined with CBD oils, capsules, and creams. It has become the reference point for many people exploring plant-based wellness options.
Kanna (Sceletium tortuosum) is less well known in Europe — but among those who have explored the nootropics and botanical wellness space, it is attracting serious attention. The two plants are often compared by people who have tried CBD and are curious whether kanna offers something different.
This article compares both plants honestly — their origins, chemistry, what research exists, their legal status, and the practical differences that matter when choosing between them.
What Is CBD?
CBD, or cannabidiol, is one of over a hundred cannabinoids found in the Cannabis sativa plant. Unlike THC (tetrahydrocannabinol), CBD is non-intoxicating and does not produce a high. It was legalised across the EU when derived from hemp varieties containing less than 0.2% THC, and has since become one of the most commercially successful natural wellness products in Europe.
CBD interacts primarily with the endocannabinoid system — a network of receptors (CB1 and CB2) found throughout the body and brain. Research into the endocannabinoid system is extensive and ongoing. CBD has been studied in a range of contexts, and one CBD-based pharmaceutical (Epidiolex) has received approval for specific epilepsy conditions — though this is distinct from the general wellness CBD products available in shops.
CBD products vary enormously in quality, concentration, and bioavailability. Full-spectrum, broad-spectrum, and isolate formats each have different cannabinoid profiles, and the supplement market is still largely unregulated in terms of what is actually in each product.
What Is Kanna (Sceletium tortuosum)?
Kanna is a succulent plant native to South Africa with a well-documented ethnobotanical history. For centuries the San and Khoikhoi peoples of southern Africa traditionally used it — fermenting and chewing the plant material during hunting trips, social gatherings, and ceremonies. Historical records of its use date back to the late 1600s in European explorer accounts.
The active compounds are alkaloids — primarily mesembrine, mesembronone, and delta-7-mesembrenone. Research into these alkaloids is ongoing. Scientists have identified potential interactions with serotonin transporters and phosphodiesterase-4 (PDE4), though this research is still developing and no clinical conclusions for general wellness use should be drawn from it.
Modern standardized extracts concentrate these alkaloids to verified, consistent percentages. When purchasing kanna extract, a Certificate of Analysis (COA) from a third-party laboratory confirming the alkaloid profile is the minimum standard of quality assurance.
Different Plants, Different Chemistry
CBD and kanna work through entirely different mechanisms — and this is the most important thing to understand when comparing them.
CBD interacts with the endocannabinoid system, which is involved in a wide range of physiological processes including pain perception, immune response, and neurological function. Its effects are broad and distributed across multiple body systems.
Kanna alkaloids, based on current research, appear to interact with serotonin pathways and PDE4 — mechanisms associated with mood and cognitive processes specifically. These are separate systems from the endocannabinoid system.
Neither plant has been approved as a medicine or evaluated by EFSA for health claims. Both are sold as botanical products in the EU wellness market.
Traditional and Reported Use: What Do People Say?
CBD users commonly report: A general sense of relaxation and calm. Many describe it as taking the edge off without feeling intoxicated. Popular uses in the community include general stress support, sleep, and physical discomfort. Effects tend to be subtle and vary considerably between individuals and products.
Kanna users commonly report: A somewhat more defined character — users frequently describe a mood-lifting quality alongside a sense of calm and, in some cases, greater mental clarity and sociability. Some users describe kanna as feeling more "targeted" than CBD in terms of its effect on mood specifically. Others notice little effect. As always, individual responses vary considerably and these are anecdotal accounts only.
Neither set of reported experiences constitutes a health claim, and no clinical outcomes are implied.
Onset, Duration, and Format
CBD is available in many formats — oils (sublingual), capsules, edibles, topicals, and beverages. Sublingual oils typically show effects within 15–45 minutes and last 4–6 hours. Oral formats take longer (1–2 hours) due to digestion. Topicals act locally and do not enter the bloodstream meaningfully. Bioavailability varies considerably by format.
Kanna extract is most commonly available as a standardized powder. Users report onset within 20–45 minutes and a duration of approximately 2–4 hours. Because it is a concentrated extract, small measured amounts are used — typically in the range of 25–100mg for a 5% standardized extract, though this is community-reported and not a clinical dosing recommendation.
Quality and Standardization: A Key Practical Difference
This is an area where the two markets differ significantly in maturity — and where kanna has a structural advantage that is often overlooked.
CBD market quality issues:
The CBD market in Europe, despite its growth, has well-documented quality consistency problems. Multiple independent analyses of commercial CBD products have found that a significant percentage contain either less CBD than labelled, more THC than legally permitted, or contaminants. Without a COA from a reputable third-party laboratory, it is difficult to know what you are actually purchasing.
Kanna extract standardization:
Quality standardized kanna extracts are produced to pharmaceutical-adjacent specifications, with COAs confirming alkaloid percentages, pesticide screening, heavy metal testing, and microbial analysis — all tested to European Pharmacopoeia (Ph.Eur.) standards. This level of documentation is not universal in the CBD market.
When purchasing either product, always request or look for a published COA. For kanna extracts specifically, confirm that the mesembrine percentage is verified by GC-MS or equivalent analytical method — not simply claimed on the label.
Legal Status in Spain and the EU
Both CBD and kanna are legal across the EU, but with important distinctions.
CBD is legal in Spain and across the EU when derived from hemp with less than 0.2% THC. However, its regulatory classification has been a moving target. The EU briefly classified CBD as a novel food in 2019, creating uncertainty for sellers. The market has largely stabilised but regulatory nuances around specific product formats (particularly ingestible oils and capsules) vary by member state and continue to evolve.
Kanna is legal throughout the EU without restriction. It is not classified as a novel food, not scheduled as a controlled substance in any EU member state, and faces no current regulatory uncertainty. It can be imported from South Africa, sold online, and shipped across the EU without legal complications.
For buyers and sellers in Spain and the EU, kanna's clean and stable legal status is a practical advantage over CBD's more complex regulatory history.
Price Comparison
CBD products vary enormously in price depending on concentration and format. A quality 10% CBD oil (10ml, approximately 1000mg CBD) in Spain typically costs €30–60. On a per-milligram basis, quality CBD is not cheap.
Kanna extract at 5% standardization is used in much smaller amounts — typically 25–100mg per use. A 1g quantity of quality standardized extract represents approximately 10–40 individual uses depending on the amount used, at a cost broadly comparable to or lower than equivalent CBD on a per-use basis.
Price per use comparison is more meaningful than headline product price for either botanical.
Can You Combine Kanna and CBD?
This is a question that comes up in the nootropics community. There is no known dangerous interaction between kanna and CBD based on their respective mechanisms — CBD acts on the endocannabinoid system, kanna on serotonin and PDE4 pathways, which are distinct.
However, combining any two active botanicals introduces variables that neither has been studied for in combination. If you take prescription medications — particularly anything affecting serotonin (SSRIs, SNRIs, MAOIs) — consult a healthcare professional before using kanna regardless of whether you also use CBD. The same applies to any other botanical combination.
Nothing here constitutes a recommendation to combine these products.
Which Plant Might Be More Relevant for You?
This is an informational comparison only. That said, the documented differences suggest different profiles of interest.
CBD may be of more interest if:
- You are already familiar with and respond well to it
- You are primarily interested in physical discomfort or sleep support
- You prefer a very widely researched botanical with a long commercial track record in Europe
- You want topical application options
Kanna may be of more interest if:
- You have tried CBD and found the effects too subtle or not quite what you were looking for
- You are specifically curious about botanicals researched for serotonin pathway interactions
- You want a product with a fully standardized, verified alkaloid profile and pharmaceutical-grade COA
- You want a legally uncomplicated option with no regulatory uncertainty in the EU
- You are interested in the cognitive and mood-specific focus of current kanna research
Many people in the botanical wellness space use both at different times for different purposes. They are not direct substitutes — they work differently and the experiences users describe are distinct.
MT55 vs MZ0: Choosing Your Kanna Extract
If kanna is of interest, understanding the two main standardized extract types is useful.
MZ0 has an alkaloid profile of approximately 85% mesembrine, 13% mesembronone, and 2% delta-7-mesembrenone. Users commonly describe it as having a more uplifting, energising character and tend to prefer it earlier in the day.
MT55 has approximately 72% mesembrine, 22% mesembronone, and 6% delta-7-mesembrenone. The higher mesembronone content is associated in user reports with a more calming, settling quality. Many users prefer it for evening use.
These alkaloid percentages should always be verified in the supplier's COA — not taken on trust from product labelling alone.
Summary
CBD and kanna are both well-established botanicals with long histories of human use and growing scientific interest. They work through different mechanisms, offer different reported experiences, and occupy slightly different spaces in the natural wellness landscape.
CBD has the advantage of widespread availability, extensive research, and mainstream familiarity. Kanna has the advantage of a cleaner regulatory status in the EU, higher standardization potential, and a distinct mechanism that some users find more relevant to mood and cognitive aspects of general wellbeing.
Neither is a medicine. Neither has been evaluated for health claims by EFSA or any EU medicines body. Both are best approached with realistic expectations, quality sourcing, and an understanding of your own health context.
If you are curious about kanna, sourcing from a supplier with full batch-level COAs tested to European Pharmacopoeia standards is the baseline requirement for quality assurance.
Sceletic Co. sources its Sceletium tortuosum extracts directly from licensed producers in South Africa, with full batch-level laboratory testing and published Certificates of Analysis. MT55 and MZ0 extracts are available for delivery across Spain and the EU.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Kanna extracts sold by Sceletic Co. are raw botanical specimens intended for research and educational purposes only, and are not intended for human consumption, nor sold as food supplements or medicines. Always consult a qualified healthcare professional before using any botanical product, particularly if you are taking prescription medications or have an existing health condition. Nothing in this article has been evaluated by the European Food Safety Authority or any medicines regulatory body.